Skip to main content

Remote Job Finders (RJF)

Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck

Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s ‘disease agnostic’ pipeline and approach to business development.

Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.

Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms

On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations.

BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat

In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma raised its full-year revenue forecast.
Scroll to top